SecBot SecBot
8-K ·Filed Nov 13, 2026

ARAY

ACCURAY INC
BEARISH
Impact 6/10
Horizonweeks Processed3d 22h ago SEC0001437749-26-036943
8-K context-dependent: Items 3.02, 3.03, 7.01
Actionable Insight ▼ Bearish

The TCW preferred stock is deeply in-the-money relative to the current market cap, giving TCW the ability to convert into a controlling common equity stake. Monitor for any conversion notices and the company's ability to service the 8% preferred dividend. The covenant holiday runs through Dec 2027, after which financial tests resume.

DirectionBearish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Accuray closed its previously announced financing with TCW, issuing 55,000 shares of Series A convertible preferred stock for $55M ($15M cash plus $40M debt conversion). The company also executed a 1-for-40 reverse stock split and increased authorized common shares to 400M before the split. Outstanding warrants for ~27.6M pre-split shares were canceled. The transaction reduces debt, adds liquidity, and waives financial covenants through Dec 2027, but creates a senior preferred claim and gives TCW significant governance control.

Key Financial Metrics

Offering Size
$55.0M

Key Facts

  • TCW exchanged $40M of its term loan for Series A convertible preferred stock and invested $15M cash, for total consideration of $55M.
  • 55,000 shares of Series A convertible preferred stock issued at $1,000 per share, senior to common stock with 8% cumulative dividend.
  • Conversion price set at $20.00 per share (post-split), convertible into 50 common shares per $1,000 of stated value.
  • 1-for-40 reverse stock split effective Nov 9, 2026; authorized common shares reduced from 400M to 10M post-split.
  • Outstanding warrants to purchase ~27.6M pre-split shares (at $1.25-$1.68) were canceled upon closing.
  • Financial covenants under existing term loan waived through Dec 31, 2027; first test date Mar 31, 2028.
  • Delayed draw term loan of up to $5M available subject to conditions.
  • Board reduced from 8 to 7 members; TCW has right to appoint 2 directors.
  • Market cap is $10M; the $55M preferred issuance is 5.5x the market cap, representing massive dilution potential.

Financial Impact

$55M total consideration ($15M cash + $40M debt conversion); preferred stock senior to common with 8% dividend; conversion price of $20/share post-split implies massive dilution relative to $10M market cap

dilutiondebtliquiditycapital structure

Risk Factors

  • Massive potential dilution: the $55M preferred at $20 conversion price could swamp the $10M market cap common equity
  • TCW now controls 2 of 7 board seats and has veto power over senior capital issuance
  • Company remains highly leveraged with a delayed draw facility and resumed covenant testing in 2028
  • Reverse stock split and low share price may indicate ongoing listing compliance risk

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-036943
Exhibit: ex_1043816.htm0001437749-26-036943
Exhibit: ex_1043815.htm0001437749-26-036943
Exhibit: ex_1043814.htm0001437749-26-036943
Document: aray20261111_8k.htm0001437749-26-036943
Document: 0001437749-26-036943-index-headers.html0001437749-26-036943
Document: 0001437749-26-036943-index.html0001437749-26-036943
Document: 0001437749-26-036943.txt0001437749-26-036943

Track record

21 reports on ARAY

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +76.06% at T+60 after the Aug 19, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 17, 2026today SC 13D/A Neutral 4/10 Entry $2.50 Now $2.41 −3.40% settles Nov 24
  2. Nov 13, 20263d ago 8-K Bearish 6/10 Viewing Entry $3.16 Now $2.41 +23.58% settles Nov 23
  3. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.1239 to $0.0770 Now $2.41 +1849.15% ▼ −37.85% −41.14% vs SPY
  4. Nov 4, 202612d ago Press Release Bearish 6/10 No price data
  5. Nov 4, 202612d ago 8-K Bearish 6/10 Entry $0.1239 to $0.0770 Now $2.41 −1849.15% ▲ +37.85% +41.14% vs SPY
  6. Oct 21, 202627d ago Press Release Neutral 1/10 Entry $0.1340 to $0.1400 Now $2.41 +1702.24% ▲ +4.48% +3.77% vs SPY
  7. Oct 16, 20264w ago DEF 14A Bearish 6/10 Entry $5.60 to $4.80 Now $2.41 +56.88% ▲ +14.29% +14.14% vs SPY
  8. Oct 13, 20265w ago 8-K Neutral 4/10 Entry $0.1751 to $0.1370 Now $2.41 +1279.21% ▼ −21.76% −22.21% vs SPY
  9. Oct 7, 20265w ago 3 Neutral 2/10 Entry $0.2414 to $0.1738 Now $2.41 +900.41% ▼ −28.00% −27.73% vs SPY
  10. Oct 6, 20266w ago 8-K Bearish 6/10 Entry $0.2534 to $0.1751 Now $2.41 −853.04% ▲ +30.90% +29.92% vs SPY
Showing 10 of 21

US Market Status

Market Open · Closes in 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026